Product Images Doxorubicin Hydrochloride

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 7 images provide visual information about the product associated with Doxorubicin Hydrochloride NDC 0143-9093 by Hikma Pharmaceuticals Usa Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

structure - doxorubicin hcl for injection usp 1

structure - doxorubicin hcl for injection usp 1

fig. 1 - doxorubicin hcl for injection usp 2

fig. 1 - doxorubicin hcl for injection usp 2

Figure 1 shows a meta-analysis of disease-free survival. The hazard ratio for each trial is listed, as well as the 95% confidence interval. The trials include NSABP B-15, SEOSA, ONCOFRANCE, SE Sweden BCG A, NSABC Israel Bro283, and Austrian BCSG 3. The meta-analysis compares six studies that used Doxo with CMF (not identified). The graph shows that Doxo is better than CMF in some cases and worse in others. The text ends with a boundary for non-inferiority with CMF, which is retained at 75% of the CMF effect.*

fig. 2 - doxorubicin hcl for injection usp 3

fig. 2 - doxorubicin hcl for injection usp 3

10 mg vial - doxorubicin hcl for injection usp 4

10 mg vial - doxorubicin hcl for injection usp 4

This is a medication called DOXOrubicin HCI for injection, which is available only by prescription. Each vial contains 10mg of Doxorubicin HCI, USP and 50mg of Lactose Monohydrate, NF. The vial is single-dose and should be used for intravenous use only after reconstitution with 5mL of 0.9% Sadium Chioride Injection, USP. The usual dosage must be checked in the package insert. Unreconstituted vial should be stored at 20° to 25°C (68 10 77°F) [See USP] away from light and should be used before the expiration date. After reconstitution, any unused portion of the vial should be discarded. Severe complications like cellults, vesication and tissue necrosis can occur if the drug is extravasated during administration. The product is distributed by Hikma.*

50 mg vial - doxorubicin hcl for injection usp 5

50 mg vial - doxorubicin hcl for injection usp 5

This is a prescription drug with the National Drug Code 0143-9093-01. It contains Doxorubicin HCI to be used intravenously after reconstitution with 25 mL 0.9% Sodium Chloride Injection USP. Each single-dose vial contains 50 mg of Doxorubicin HCI and 250 mg of Lactose Monohydrate, NF. The drug should be stored between 20° to 25°C till use while protecting it from light. The vial should be discarded if some portion of the drug is unused. Severe cellulitis, vesication, and fissure necrosis will occur if extravasation happens during administration. The manufacturer is THYMOORGAN PHARMAZIE GribH, Germany, and the drug is distributed by Hikina, Berkeley Heights, 07922.*

Representative Carton Serialization Image - doxorubicin hcl for injection usp 6

Representative Carton Serialization Image - doxorubicin hcl for injection usp 6

This is a product code label that contains a lot number "T Lot", an alphanumeric code "ABCDE12345", and an expiration date "MMMYYYY". Additionally, the label displays a Global Trade Item Number (GTIN) "00301234567896" and a serial number (SN) "12345678901234".*

Representative Carton Serialization Image - doxorubicin hcl for injection usp 7

Representative Carton Serialization Image - doxorubicin hcl for injection usp 7

This text provides product identification and traceability information. The Global Trade Item Number (GTIN) is 0301234567896, while the Serial Number (SN) is 1234567890123. The product expiration date is indicated as "MMMYYYY", and the LOT number is ABCDE12345.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.